Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airway pressure; CPAP masks; Simeox for airway clearance treatment; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Beverly, Massachusetts.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $349M | $-10M | $-23M | $-22M | -11.8% | 3.9% | -36.6% |
| 2024 | $336M | $-22M | $-36M | $-11M | -20.6% | 6.4% | -65.0% |
| 2023 | $316M | $-58M | $-102M | $-30M | -50.0% | -16.3% | 22.3% |
| 2022 | $377M | $-10M | $-84M | $-59M | -28.2% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 348.67 |
| Operating Revenue | 348.67 |
| Cost Of Revenue | 194.40 |
| Gross Profit | 154.26 |
| Operating Expense | 184.47 |
| Research And Development | 19.40 |
| Selling General And Administration | 165.07 |
| Total Expenses | 378.88 |
| Operating Income | -30.21 |
| Total Operating Income As Reported | -30.21 |
| EBITDA | -9.55 |
| Normalized EBITDA | -9.55 |
| EBIT | -30.21 |
| Interest Income | 4.38 |
| Net Interest Income | 4.38 |
| Other Non Operating Income Expenses | 2.44 |
| Other Income Expense | 2.44 |
| Interest Income Non Operating | 4.38 |
| Net Non Operating Interest Income Expense | 4.38 |
| Pretax Income | -23.38 |
| Tax Provision | -0.63 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | 0 |
| Net Income Continuous Operations | -22.75 |
| Net Income From Continuing And Discontinued Operation | -22.75 |
| Net Income From Continuing Operation Net Minority Interest | -22.75 |
| Net Income | -22.75 |
| Net Income Common Stockholders | -22.75 |
| Net Income Including Noncontrolling Interests | -22.75 |
| Normalized Income | -22.75 |
| Diluted NI Availto Com Stockholders | -22.75 |
| Basic Average Shares | 26.60 |
| Diluted Average Shares | 26.60 |
| Reconciled Depreciation | 20.66 |
| Reconciled Cost Of Revenue | 194.40 |
| Total Unusual Items | 0 |
| Total Unusual Items Excluding Goodwill | 0 |
| Special Income Charges | 0 |
| Write Off | 0 |
| Impairment Of Capital Assets | - |
| General And Administrative Expense | 67.38 |
| Other Gand A | 67.38 |
| Gain On Sale Of Ppe | - |
| Rent Expense Supplemental | 18.77 |
| Selling And Marketing Expense | 97.69 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Inogen, Inc.this co. | INGN | $171M | -7.51 | 0.89 | -11.8% | -8.86 |
| MediWound Ltd. | MDWD | $186M | -7.78 | 4.26 | -54.7% | -8.81 |
| Stereotaxis, Inc. | STXS | $184M | -8.49 | 13.63 | -160.5% | -8.55 |
| Quanterix Corporation | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Journey Medical Corporation | DERM | $171M | -14.98 |
| - |
| - |
| - |
| - |
| 5.38 |
| -35.9% |
| -51.87 |
| ADC Therapeutics SA | ADCT | $168M | -1.18 | -0.90 | 76.7% | -0.27 |
| Protalix BioTherapeutics, Inc. | PLX | $162M | - | 3.36 | -13.7% | - |
| Korro Bio, Inc. | KRRO | $161M | -1.38 | 3.13 | -228.0% | -2.20 |
| CVRx, Inc. | CVRX | $156M | - | 3.97 | -135.6% | - |
| Peer Median | - | -4.72 | 3.66 | -45.5% | -5.38 | |